Oncology · Surgery ·
Long-term outcomes after CRS-HIPEC for colorectal peritoneal metastases
A consecutive cohort study evaluated 440 patients with colorectal cancer and peritoneal metastases who underwent complete cytoreductive surgery and HIPEC. Median overall survival was 50.2 months, although recurrence occurred in 71.4% of patients during a median follow-up of 35.2 months.
- Median overall survival was 50.2 months.
- Median disease-free survival was 9.7 months.
- Recurrence occurred in 71.4% of patients.
- Higher disease burden and nodal involvement predicted poorer outcomes.
This consecutive cohort study assessed survival and recurrence after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) in 440 patients with colorectal cancer and peritoneal metastases who achieved complete macroscopic cytoreduction. Outcomes included overall survival (OS), disease-free survival (DFS), peritoneal recurrence-free survival (PRFS) and recurrence patterns. Median follow-up was 35.2 months; 43.1% received induction systemic therapy.
Median OS was 50.2 months (95% CI 44.3–56.2), while median DFS was 9.7 months (95% CI 8.3–11.1). Recurrent disease developed in 71.4% of patients, including peritoneal recurrence in 54.8%, lung recurrence in 22.9% and liver recurrence in 19.1%. Higher Peritoneal Cancer Index, lymph node involvement, ASA score above 2 and a right-sided primary tumor were associated with worse OS. Neither induction therapy nor HIPEC regimen correlated with PRFS.
The findings describe outcomes in selected patients treated with complete cytoreduction and support the possibility of prolonged survival in this setting. Recurrence was common, and the authors report that approximately 30% had long-term survival indicative of cure. As a cohort study, these results do not establish comparative treatment benefit; selection for surgery and the median follow-up limit interpretation of long-term cure rates.
In practice
For patients with colorectal cancer and peritoneal metastases selected for complete cytoreduction and HIPEC, this cohort reports median overall survival of 50.2 months, but median disease-free survival was 9.7 months and recurrence affected 71.4%. Higher Peritoneal Cancer Index and lymph node involvement were among factors associated with poorer outcomes. These data can inform discussions of prognosis in this selected surgical population, but the observational design does not show comparative benefit or establish that CRS-HIPEC is appropriate for other patients.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Annals of Surgical Oncology: Long-Term Survival After CRS-HIPEC for colorectal Cancer Peritoneal Metastases ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.